-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The response of psoriasis patients to biologic drugs may be as low as 30%
.
In other inflammatory diseases, the positive effect of adding methotrexate to adalimumab has been reported
Quality of Life
Measure the blood concentration of Adali before taking ADA and MTX, and collect treatment emergency adverse events (TEAE)
.
46 patients from 12 sites were enrolled, 93.
According to the assessment of researchers and patients, none of the patients (0/46) and 15.
2% (7/46; 95%CI=4.
8%~25.
6%) of the patients achieved satisfactory response to the treatment at baseline, that is, the score ≥ 4 points (1~5 points)
.
At 16 weeks, the above proportions increased to 50.
Figure 1 The effect of adding methotrexate to psoriasis patients treated with Adalimumab
.
(A) Baseline, 8th, 16th and 24th week satisfaction questions, response choices, and treatment satisfaction of the researcher’s assessment and patient self-assessment; satisfaction achieved is defined as high satisfaction or complete satisfaction
This study found that patients’ satisfaction with treatment and maintenance for more than 24 weeks increased significantly compared to baseline.
PASI 100 response and PGA response clearly or slightly indicate that it is necessary to evaluate whether the patient’s skin clearance rate will improve after 24 weeks
This study found that patients’ satisfaction with treatment and maintenance for more than 24 weeks increased significantly compared to baseline.
Literature source: Papp KA, Gooderham MJ, Albrecht LE, Treatment satisfaction, safety, and effectiveness of adding methotrexate to adalimumab in psoriasis patients responding sub-optimally to adalimumab in a real-world setting, Br J Dermatol 2021 Nov 08;
Papp KA, Gooderham MJ, Albrecht LE, Treatment satisfaction, safety, and effectiveness of adding methotrexate to adalimumab in psoriasis patients responding sub-optimally to adalimumab in a real-world setting, Br J Dermatol 2021 Nov 08;Leave a message here
